Identifying molecular markers for the sensitive detection of residual atypical teratoid rhabdoid tumor cells

TY - JOUR

T1 - Identifying molecular markers for the sensitive detection of residual atypical teratoid rhabdoid tumor cells

AU - Vu-Han, Tu-Lan

AU - Frühwald, Michael C

AU - Hasselblatt, Martin

AU - Kerl, Kornelius

AU - Nagel, Inga

AU - Obser, Tobias

AU - Oyen, Florian

AU - Siebert, Reiner

AU - Schneppenheim, Reinhard

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Atypical teratoid rhabdoid tumor (AT/RT), a rare and highly malignant tumor entity of the central nervous system that presents in early childhood, has a poor prognosis. AT/RTs are characterized by biallelic inactivating mutations of the gene SMARCB1 in 98% of patients; these mutations may serve as molecular markers for residual tumor cell detection in liquid biopsies. We developed a marker-specific method to detect residual AT/RT cells. Seven of 150 patient samples were selected, each with a histological and genetically ascertained diagnosis of AT/RT. Tumor tissue was either formalin fixed or fresh frozen. DNA was extracted from the patients' peripheral blood leukocytes (PBL) and cerebrospinal fluid (CSF). Multiplex ligation-dependent probe amplification, DNA sequencing, and fluorescence in situ hybridization were used to characterize the tumors' mutations. Residual tumor cell detection used mutation-specific primers and real-time PCR. The detection limit for the residual tumor cell search was 1-18%, depending on the quality of the template provided. The residual tumor cell search in PBL and CSF was negative for all seven patients. The SMARCB1 region of chromosome 22 is prone to DNA double-strand breaks. The individual breakpoints and breakpoint-specific PCR offer the option to detect minimal residual tumor cells in CSF or blood. Even if we did not detect minimal residual tumor cells in the investigated material, proof of principle for this method was confirmed.

AB - Atypical teratoid rhabdoid tumor (AT/RT), a rare and highly malignant tumor entity of the central nervous system that presents in early childhood, has a poor prognosis. AT/RTs are characterized by biallelic inactivating mutations of the gene SMARCB1 in 98% of patients; these mutations may serve as molecular markers for residual tumor cell detection in liquid biopsies. We developed a marker-specific method to detect residual AT/RT cells. Seven of 150 patient samples were selected, each with a histological and genetically ascertained diagnosis of AT/RT. Tumor tissue was either formalin fixed or fresh frozen. DNA was extracted from the patients' peripheral blood leukocytes (PBL) and cerebrospinal fluid (CSF). Multiplex ligation-dependent probe amplification, DNA sequencing, and fluorescence in situ hybridization were used to characterize the tumors' mutations. Residual tumor cell detection used mutation-specific primers and real-time PCR. The detection limit for the residual tumor cell search was 1-18%, depending on the quality of the template provided. The residual tumor cell search in PBL and CSF was negative for all seven patients. The SMARCB1 region of chromosome 22 is prone to DNA double-strand breaks. The individual breakpoints and breakpoint-specific PCR offer the option to detect minimal residual tumor cells in CSF or blood. Even if we did not detect minimal residual tumor cells in the investigated material, proof of principle for this method was confirmed.

KW - Adolescent

KW - Adult

KW - Base Sequence

KW - Brain Neoplasms

KW - Child

KW - Chromosomal Proteins, Non-Histone

KW - Chromosome Breakpoints

KW - Chromosomes, Human, Pair 2

KW - DNA Mutational Analysis

KW - DNA-Binding Proteins

KW - Humans

KW - Middle Aged

KW - Neoplasm, Residual

KW - Rhabdoid Tumor

KW - Sequence Analysis, DNA

KW - Sequence Deletion

KW - Teratoma

KW - Tissue Preservation

KW - Transcription Factors

KW - Tumor Markers, Biological

KW - Tumor Suppressor Proteins

KW - Young Adult

U2 - 10.1016/j.cancergen.2014.05.008

DO - 10.1016/j.cancergen.2014.05.008

M3 - SCORING: Journal article

C2 - 25016934

VL - 207

SP - 390

EP - 397

JO - CANCER GENET-NY

JF - CANCER GENET-NY

SN - 2210-7762

IS - 9

ER -